Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Atazanavir (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Acronyms ATLAS; ATLAS 2; ATLAS-M
- 10 Mar 2017 Results of substudy(n=201) assessing the impact of the atazanavir/ritonavir+lamivudine dual therapy versus the three-drug continuing atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir after 48 weeks, published in the Journal of Antimicrobial Chemotherapy.
- 16 Feb 2017 Results (n=140) assessing the impact at 96 weeks of the dual therapy versus the triple therapy on the HIV-1 cellular reservoir presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 15 Jan 2017 Primary endpoint proportion of patients with viral load 50 copies/mL (Non inferiority efficacy (superiority on post hoc analysis) of atazanavir/ritonavir + lamivudine arm) has been met as per results published in the Journal of Antimicrobial Chemotherapy.